By using patient-derived conditionally reprogrammed prostate cancer cells, it was discovered that LA-12 improves cell death caused by TRAIL, a member of tumor necrosis factor (TNF) family 168, and combinatorial therapy of TRAIL with LA-12/cisplatin killed prostate cancer cells more successfully (67), which provides implications for new combinations of medications for prostate cancer. The gene discussed is TNF; the disease is prostate cancer.